Saturday, February 03, 2007

Multiple Sclerosis International Federation

Clinical trial of MBP8298 expands to United States

source: MS Society of Canada

BioMS, an Edmonton-based biotechnology company in Canada, has announced it has received permission from the US Food and Drug Administration (FDA) to carry out a phase III clinical trial of its experimental drug MBP8298 as a potential treatment for secondary-progressive MS.

read more

Study refutes prior claim that blood test can predict course of MS

source: US National MS Society

A new study refutes a previous claim that the presence of myelin-specific antibodies in serum could predict whether a person who had experienced a single episode of nerve dysfunction would eventually develop multiple sclerosis.

read more


Research News


Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia

This study on brain tissue samples from MS patients helps to clarify the role of a specific immunological molecule involved in the inflammatory response, providing interesting insights into the pathogenesis of this disease.

authors: Li Y, Chu N, Hu A, Gran B, Rostami A, Zhang GX.

source: Brain. 2007 Feb;130(Pt 2):490-501. Epub 2006 Sep 26.

read more

A second major histocompatibility complex susceptibility locus for multiple sclerosis

This genetic study of MS helps to clarify the role of a gene involved in the development of the immune system, which may influence susceptibility to the disease.

authors: Yeo TW, De Jager PL, Gregory SG, Barcellos LF, Walton A, Goris A, Fenoglio C, Ban M, Taylor CJ, Goodman RS, Walsh E, Wolfish CS, Horton R, Traherne J, Beck S, Trowsdale J, Caillier SJ, Ivinson AJ, Green T, Pobywajlo S, Lander ES, Pericak-Vance MA, Haines JL, Daly MJ, Oksenberg JR, Hauser SL, Compston A, Hafler DA, Rioux JD, Sawcer S.

source: Ann Neurol. 2007 Jan 24

read more

Soluble Nogo-A, an inhibitor of axonal regeneration, as a biomarker for multiple sclerosis

In this study of CSF of patients with MS, the authors studied the role of Nogo-A, a component of CNS myelin involved in the poor regenerative response of neurons. They found it to be a useful marker of failure of neuronal regrowth in this disease.

authors: Jurewicz A, Matysiak M, Raine CS, Selmaj K.

source: Neurology. 2007 Jan 23;68(4):283-7.

read more

Caregiver burden in multiple sclerosis: The impact of neuropsychiatric symptoms

The authors explored the impact of MS patients’ psychiatric symptoms on caregivers, finding them to be a major factor responsible for distress and poor quality of life.

source: J Neurol Neurosurg Psychiatry. 2007 Jan 19

read more

Association between parasite infection and immune responses in multiple sclerosis

This follow-up study evaluated whether parasite infections could alter the course of MS. The authors concluded that the changes in immunological response induced by parasite infections can reduce the disease course severity.

authors: Correale J, Farez M.

source: Ann Neurol. 2007 Jan 17

read more

Antimyelin antibodies with no progression to multiple sclerosis

The authors studied the CSF of patients with their first clinical episode suggestive of MS. They evaluated the association between the presence of antibodies to myelin and a greater chance of developing MS, but found no clear correlation.

authors: Pelayo R, Tintore M, Montalban X, Rovira A, Espejo C, Reindl M, Berger T.

source: N Engl J Med. 2007 Jan 25;356(4):426-8

read more

Lack of association between antimyelin antibodies and progression to multiple sclerosis

This study, together with the findings in the previously mentioned study, provides definitive evidence against the use of antibodies to two components of myelin to predict the course of the disease in patients with a single clinical episode suggestive of MS.

authors: Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung HP, Polman CH, Miller DH, Montalban X, Barkhof F, Bauer L, Dahms S, Lindberg R, Kappos L, Sandbrink R.

source: N Engl J Med. 2007 Jan 25;356(4):371-8.

read more

Other Research News

EFNS Congress 2007

The 11th Congress of the European Federation of Neurological Societies is taking place in Brussels, Belgium, August 25-28, 2007. The deadline for abstract submission is 15 February, and there are reduced registration fees if you register before 1 June.

read more


Profile of the Month : January 2007

Stuart Schlossman

Country: USA
Age: 48
Year of diagnosis: 1998
Occupation: Retired, formerly in International Sales and Marketing

"I hope that one day there is a cure for all of us living with MS."

English Italiano Espanol Deutsch Francais Russian

read more



MSIF News


Chief Executive visits German MS Society

Peer Baneke, MSIF's Chief Executive, visited the German MS Society (DMSG) from 24-26 January, 2007.

read more

MSIF's Du Pré Grants - nominations due March 12

MSIF is offering sponsorship opportunities for young MS researchers to work in another country during 2007.

read more

MSIF MS Directory

The MSIF MS Directory is now available on the MSIF website. The directory is an easily downloadable document containing the contact details for MSIF’s 43 member and associate member societies.

read more



0 Comments:

Post a Comment

<< Home